# GLP-1 Drugs Offer Real Hope for People With Pain or Addiction > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/glp-1-receptor-agonists-pain-management/ > **Published:** 2026-04-06T20:03:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:29:02-04:00 > **Clinical Summary:** Explore how GLP-1 receptor agonists pain management is emerging as a promising approach for chronic pain and addiction treatment. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Pain Management[Addiction Medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/)Glp-1[Chronic Pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/)Substance Use Why This MattersGLP-1 receptor agonists are showing promise beyond diabetes and weight management, with emerging evidence for pain reduction and [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). This represents a potential paradigm shift for clinicians managing chronic pain patients who often have limited, high-risk options like opioids. Clinical Summary GLP-1 receptor agonists, originally developed for diabetes management, are demonstrating therapeutic potential in pain and addiction medicine through mechanisms that may include neuroinflammation reduction and reward pathway modulation. Early clinical observations suggest these medications could provide analgesic effects while simultaneously reducing addictive behaviors, though rigorous controlled trials are still needed to establish efficacy and safety profiles for these indications. The dual action could be particularly relevant for patients with comorbid pain and substance use disorders. Dr. Caplan’s Take“I’m cautiously optimistic about GLP-1s expanding our toolkit, especially for patients caught between inadequate pain control and addiction risk. However, we need robust clinical trial data before making these off-label leaps in vulnerable populations.” Clinical Perspective🧠 Clinicians should monitor emerging research on GLP-1s for pain and addiction while maintaining current evidence-based approaches. For patients already on GLP-1 therapy, document any changes in pain levels or substance use behaviors. Consider these potential benefits when weighing treatment options for complex patients with metabolic, pain, and addiction comorbidities. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20GLP-1%20Drugs%20Offer%20Real%20Hope%20for%20People%20With%20Pain%20or%20Addiction%20%40drcaplan&url=https%3A//www.painnewsnetwork.org/stories/2026/4/6/glp-1-drugs-offer-hope-for-pain-and-addiction)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.painnewsnetwork.org/stories/2026/4/6/glp-1-drugs-offer-hope-for-pain-and-addiction)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20GLP-1%20Drugs%20Offer%20Real%20Hope%20for%20People%20With%20Pain%20or%20Addiction%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.painnewsnetwork.org/stories/2026/4/6/glp-1-drugs-offer-hope-for-pain-and-addiction)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.painnewsnetwork.org/stories/2026/4/6/glp-1-drugs-offer-hope-for-pain-and-addiction](https://www.painnewsnetwork.org/stories/2026/4/6/glp-1-drugs-offer-hope-for-pain-and-addiction) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance level of this cannabis research?](#What_is_the_clinical_relevance_level_of_this_cannabis_research) - [What medical conditions does this cannabis research focus on?](#What_medical_conditions_does_this_cannabis_research_focus_on) - [How does GLP-1 relate to this cannabis study?](#How_does_GLP-1_relate_to_this_cannabis_study) - [Why is this considered “emerging findings” worth monitoring?](#Why_is_this_considered_8220emerging_findings8221_worth_monitoring) - [What should clinicians know about this cannabis research?](#What_should_clinicians_know_about_this_cannabis_research) - [Related](#Related) ## FAQ #### What is the clinical relevance level of this cannabis research? This study has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This means the findings represent emerging developments or policy changes that healthcare providers should monitor closely for potential clinical applications. #### What medical conditions does this cannabis research focus on? The research primarily addresses pain management and chronic pain conditions. It also intersects with addiction medicine, suggesting the study may examine cannabis as an alternative or adjunct therapy for patients with pain-related substance use concerns. #### How does GLP-1 relate to this cannabis study? GLP-1 medications appear to be included in this research, likely examining potential interactions or comparative effects with cannabis treatments. This could involve studying metabolic effects, appetite regulation, or combined therapeutic approaches for patients using both medication types. #### Why is this considered “emerging findings” worth monitoring? The study represents new or developing evidence in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) that hasn’t yet reached standard practice guidelines. Healthcare providers should track these findings as they may influence future treatment protocols or regulatory policies regarding medical cannabis use. #### What should clinicians know about this cannabis research? Clinicians should be aware that this research spans multiple therapeutic areas including pain management and addiction medicine. The findings may provide insights into cannabis efficacy, safety profiles, or drug interactions that could inform patient care decisions in these specialties. Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [GLP-1s show promise in treating addiction – MSN](https://cedclinic.com) This article explores the potential of GLP-1 medications in addiction treatment, highlighting recent clinical findings and future research directions. [Read More](https://cedclinic.com) [Obesity Treatment Is Expanding Beyond Medication](https://cedclinic.com/obesity-treatment-is-expanding-beyond-medication/) Learn about new approaches in obesity treatment, including the expanding role of GLP-1 receptor agonists beyond traditional medication use. [Explore Now](https://cedclinic.com/obesity-treatment-is-expanding-beyond-medication/) [Many studies show the efficacy of cannabis for inflammation. That's important because …](https://cedclinic.com/cannabis-anti-inflammatory-effects-research-clinical-insights/) Discover how [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) intersects with pain and inflammation management, complementing emerging therapies like GLP-1 receptor agonists. [Learn More](https://cedclinic.com/cannabis-anti-inflammatory-effects-research-clinical-insights/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).